40
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Ideally, an oncolytic virus will replicate preferentially in malignant cells, have the ability to treat disseminated metastases, and ultimately be cleared by the patient. Here we present evidence that the attenuated vesicular stomatitis strains, AV1 and AV2, embody all of these traits. We uncover the mechanism by which these mutants are selectively attenuated in interferon-responsive cells while remaining highly lytic in 80% of human tumor cell lines tested. AV1 and AV2 were tested in a xenograft model of human ovarian cancer and in an immune competent mouse model of metastatic colon cancer. While highly attenuated for growth in normal mice, both AV1 and AV2 effected complete and durable cures in the majority of treated animals when delivered systemically.

          Related collections

          Author and article information

          Journal
          Cancer Cell
          Cancer cell
          Elsevier BV
          1535-6108
          1535-6108
          Oct 2003
          : 4
          : 4
          Affiliations
          [1 ] Ottawa Regional Cancer Centre Research Laboratories, 501 Smyth Road, Ottawa, Ontario, Canada K1H 8L6.
          Article
          S1535610803002411
          10.1016/s1535-6108(03)00241-1
          14585354
          986170b6-4198-40b8-a193-9f8314c9c8f0

          Comments

          Comment on this article